INSR and cancer: There are two mechanisms associated with the anticancer effects of metformin: metformin lowers circulating insulin, which can bind to the highly expressed insulin receptor in cancer cells, thereby indirectly decreasing cell proliferation [1]; and metformin directly activates AMPK and subsequently inhibits mammalian target of mTOR, leading to reduced cancer-cell proliferation [2].